• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lymphomatous Meningitis From Anaplastic Lymphoma Kinase+ Anaplastic Large T-Cell Lymphoma Treated With Lorlatinib: A Case Report.

作者信息

Mellacheruvu Smitha, Sayegh Mark N, Sica R Alejandro, Cheng Haiying, Santos-Zabala Maria Laureana, Gebrael Jacob H, Hermanto Ulrich, Rosen Norman L

机构信息

Department of Hematology and Oncology, St John's Riverside Hospital, Yonkers, NY.

Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.

出版信息

JCO Precis Oncol. 2022 Feb;6:e2100250. doi: 10.1200/PO.21.00250.

DOI:10.1200/PO.21.00250
PMID:35138917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8865515/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d73d/8865515/185c790bdcd1/po-6-e2100250-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d73d/8865515/3499964d63d0/po-6-e2100250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d73d/8865515/185c790bdcd1/po-6-e2100250-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d73d/8865515/3499964d63d0/po-6-e2100250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d73d/8865515/185c790bdcd1/po-6-e2100250-g003.jpg

相似文献

1
Lymphomatous Meningitis From Anaplastic Lymphoma Kinase+ Anaplastic Large T-Cell Lymphoma Treated With Lorlatinib: A Case Report.洛拉替尼治疗间变性淋巴瘤激酶阳性间变性大T细胞淋巴瘤所致淋巴瘤性脑膜炎：一例报告
JCO Precis Oncol. 2022 Feb;6:e2100250. doi: 10.1200/PO.21.00250.
2
Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.阿来替尼诱导间质性肺病后lorlatinib 治疗间变性淋巴瘤激酶阳性非小细胞肺癌 1 例报告
J Med Case Rep. 2022 Aug 24;16(1):316. doi: 10.1186/s13256-022-03556-8.
3
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.评估洛拉替尼在中枢神经系统中的浓度与间变性淋巴瘤激酶（ALK）抑制的靶浓度的关系。
J Clin Pharmacol. 2022 Sep;62(9):1170-1176. doi: 10.1002/jcph.2056. Epub 2022 Apr 27.
4
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.洛拉替尼用于治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌：IFCT-1803 LORLATU队列研究结果
Eur J Cancer. 2022 May;166:51-59. doi: 10.1016/j.ejca.2022.01.018. Epub 2022 Mar 9.
5
Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.晚期间变性淋巴瘤激酶阳性非小细胞肺癌中洛拉替尼的耐药突变与疗效。
J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.
6
Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.洛拉替尼治疗阿来替尼和布加替尼耐药的 ALK 阳性非小细胞肺癌脑膜转移患者的成功治疗：一例报告。
Medicine (Baltimore). 2021 Oct 1;100(39):e27385. doi: 10.1097/MD.0000000000027385.
7
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.评估健康参与者中间变性淋巴瘤激酶/c-ROS 致癌基因 1 激酶抑制剂洛拉替尼的绝对口服生物利用度。
Cancer Chemother Pharmacol. 2022 Jan;89(1):71-81. doi: 10.1007/s00280-021-04368-1. Epub 2021 Oct 26.
8
Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.癌症患者中微小残留病指导下的间歇性给药：使用间歇性洛拉替尼给药成功治疗化疗耐药性间变性大细胞淋巴瘤
JCO Precis Oncol. 2022 Jun;6:e2100525. doi: 10.1200/PO.21.00525.
9
Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report.ALK基因重排的转移性结直肠癌患者对克唑替尼、阿来替尼和劳拉替尼的临床反应：一例报告
JCO Precis Oncol. 2021 May 3;5. doi: 10.1200/PO.20.00534. eCollection 2021.
10
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.洛拉替尼在间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌患者中单次和多次给药后的药代动力学：一项全球 I/II 期研究的结果。
Clin Pharmacokinet. 2021 Oct;60(10):1313-1324. doi: 10.1007/s40262-021-01015-z. Epub 2021 May 3.

引用本文的文献

1
Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas.系统性外周T细胞淋巴瘤一线治疗中的争议
Cancers (Basel). 2022 Dec 30;15(1):220. doi: 10.3390/cancers15010220.

本文引用的文献

1
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.在接受过酪氨酸激酶抑制剂（TKI）治疗后进展的 ALK 阳性或 ROS1 阳性 NSCLC 患者中，通过早期或扩展准入计划评估劳拉替尼的疗效和安全性的国际真实世界分析。
J Thorac Oncol. 2020 Sep;15(9):1484-1496. doi: 10.1016/j.jtho.2020.04.019. Epub 2020 Apr 28.
2
Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.接受劳拉替尼治疗的转移性ALK+肺癌患者神经症状迅速缓解：两例报告
BMJ Case Rep. 2019 Jul 24;12(7):e227299. doi: 10.1136/bcr-2018-227299.
3
Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
晚期间变性淋巴瘤激酶阳性非小细胞肺癌中洛拉替尼的耐药突变与疗效。
J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.
4
Clinical Management of Adverse Events Associated with Lorlatinib.洛拉替尼不良反应的临床管理。
Oncologist. 2019 Aug;24(8):1103-1110. doi: 10.1634/theoncologist.2018-0380. Epub 2019 Mar 19.
5
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.贝林妥欧单抗联合化疗治疗 CD30 阳性外周 T 细胞淋巴瘤（ECHELON-2）：一项全球性、双盲、随机、3 期临床试验。
Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.
6
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.劳拉替尼用于治疗具有ALK或ROS1重排的非小细胞肺癌：一项国际多中心、开放标签、单臂首次人体1期试验。
Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.
7
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.本妥昔单抗治疗复发或难治性系统性间变性大细胞淋巴瘤患者的5年结果
Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3.
8
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.意大利关于 brentuximab vedotin 的真实世界经验：40 例复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究结果。
Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.
9
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
10
Anaplastic large cell lymphoma in paediatric and young adult patients.儿童和青年成人患者的间变性大细胞淋巴瘤
Br J Haematol. 2016 May;173(4):560-72. doi: 10.1111/bjh.13958. Epub 2016 Feb 23.